U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H27NO2
Molecular Weight 373.4874
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CDP-840

SMILES

COC1=CC=C(C=C1OC2CCCC2)[C@H](CC3=CC=NC=C3)C4=CC=CC=C4

InChI

InChIKey=UTUUPXBCDMQYRR-HSZRJFAPSA-N
InChI=1S/C25H27NO2/c1-27-24-12-11-21(18-25(24)28-22-9-5-6-10-22)23(20-7-3-2-4-8-20)17-19-13-15-26-16-14-19/h2-4,7-8,11-16,18,22-23H,5-6,9-10,17H2,1H3/t23-/m1/s1

HIDE SMILES / InChI

Molecular Formula C25H27NO2
Molecular Weight 373.4874
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16168647 | https://www.ncbi.nlm.nih.gov/pubmed/24904269

CDP 840 hydrochloride is a potent and selective inhibitor of phosphodiesterase 4 (PDE4). This compound competitively inhibits all PDE4 isoenzymes, which in turn prevents the cleavage of phosphodiester bonds found in secondary messenger molecules. CDP-840 had been in phase II clinical trials for the treatment of asthma. However, CDP840 did not lead to changes in baseline forced expiratory volume in one second (FEV1) as compared to placebo. CDP 840 research has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.1 nM [IC50]
4.5 nM [IC50]
2.1 nM [IC50]
1.4 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
1996 Jul
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
2005 Dec 1
Patents

Patents

Sample Use Guides

Patients were allocated either 15 mg b.i.d. CDP840 or placebo for a period of 9.5 days.
Route of Administration: Oral
Incubations with microsomes prepared from different species were typically conducted under linear conditions with 80 mkM CDP-840 and 0.5 mg of microsomal protein in the presence of an NADPH-generating system. Incubations (0.5 ml) were conducted for 30 min at 37°C and were quenched by the addition of an equal volume of acetonitrile.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:06:21 UTC 2023
Edited
by admin
on Sat Dec 16 17:06:21 UTC 2023
Record UNII
OK8OFX8K7F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CDP-840
Code English
CT 1730
Code English
CDP 840
Code English
GR 259653X
Code English
CDP840
Common Name English
4-((2R)-2-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)-2-PHENYLETHYL)PYRIDINE
Systematic Name English
PYRIDINE, 4-(2-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)-2-PHENYLETHYL)-, (R)-
Systematic Name English
PYRIDINE, 4-((2R)-2-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)-2-PHENYLETHYL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID60936715
Created by admin on Sat Dec 16 17:06:21 UTC 2023 , Edited by admin on Sat Dec 16 17:06:21 UTC 2023
PRIMARY
FDA UNII
OK8OFX8K7F
Created by admin on Sat Dec 16 17:06:21 UTC 2023 , Edited by admin on Sat Dec 16 17:06:21 UTC 2023
PRIMARY
CAS
162542-90-7
Created by admin on Sat Dec 16 17:06:21 UTC 2023 , Edited by admin on Sat Dec 16 17:06:21 UTC 2023
PRIMARY
PUBCHEM
127928
Created by admin on Sat Dec 16 17:06:21 UTC 2023 , Edited by admin on Sat Dec 16 17:06:21 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY